KR102233252B1 - ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 - Google Patents

ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 Download PDF

Info

Publication number
KR102233252B1
KR102233252B1 KR1020157014693A KR20157014693A KR102233252B1 KR 102233252 B1 KR102233252 B1 KR 102233252B1 KR 1020157014693 A KR1020157014693 A KR 1020157014693A KR 20157014693 A KR20157014693 A KR 20157014693A KR 102233252 B1 KR102233252 B1 KR 102233252B1
Authority
KR
South Korea
Prior art keywords
substituted
mmol
alkyl
independently
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157014693A
Other languages
English (en)
Korean (ko)
Other versions
KR20150081338A (ko
Inventor
라이언 엠. 모슬린
슈쿤 린
데이비드 에스. 웨인스타인
스테펜 티. 로블스키
양레이 장
존 에스. 토카르스키
마이클 이. 메르츠만
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20150081338A publication Critical patent/KR20150081338A/ko
Application granted granted Critical
Publication of KR102233252B1 publication Critical patent/KR102233252B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Dermatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020157014693A 2012-11-08 2013-11-07 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 Active KR102233252B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723854P 2012-11-08 2012-11-08
US61/723,854 2012-11-08
PCT/US2013/068842 WO2014074660A1 (en) 2012-11-08 2013-11-07 ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES

Publications (2)

Publication Number Publication Date
KR20150081338A KR20150081338A (ko) 2015-07-13
KR102233252B1 true KR102233252B1 (ko) 2021-03-26

Family

ID=49667568

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157014693A Active KR102233252B1 (ko) 2012-11-08 2013-11-07 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물

Country Status (15)

Country Link
US (1) US9315494B2 (enExample)
EP (1) EP2922841B8 (enExample)
JP (1) JP6259463B2 (enExample)
KR (1) KR102233252B1 (enExample)
CN (1) CN104781252B (enExample)
AR (1) AR093403A1 (enExample)
AU (1) AU2013341185B2 (enExample)
BR (1) BR112015010244A8 (enExample)
CA (1) CA2890929A1 (enExample)
EA (1) EA028526B1 (enExample)
IL (1) IL238554A0 (enExample)
MX (1) MX2015005272A (enExample)
SG (1) SG11201503396UA (enExample)
TW (1) TWI620737B (enExample)
WO (1) WO2014074660A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35126A (es) 2012-11-08 2014-05-30 Bristol Myers Squibb Co Ojo es alfa
MX2015005561A (es) 2012-11-08 2015-07-23 Squibb Bristol Myers Co Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa).
PE20150953A1 (es) * 2012-11-08 2015-06-20 Bristol Myers Squibb Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
CN105992768B (zh) 2013-12-10 2018-04-20 百时美施贵宝公司 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
UY35935A (es) 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
WO2016001341A1 (en) * 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
WO2016022626A1 (en) * 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
KR102641263B1 (ko) 2015-06-24 2024-02-26 브리스톨-마이어스 스큅 컴퍼니 헤테로아릴 치환된 아미노피리딘 화합물
CN108026099B (zh) 2015-06-24 2020-07-10 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
KR102097878B1 (ko) * 2015-11-26 2020-04-06 노파르티스 아게 디아미노 피리딘 유도체
TWI825663B (zh) 2016-10-14 2023-12-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
MA48602A (fr) * 2016-12-13 2020-03-18 Bristol Myers Squibb Co Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha
US10336752B2 (en) 2017-03-08 2019-07-02 Nimbus Lakshmi, Inc. TYK2 inhibitors, uses, and methods for production thereof
TW201900640A (zh) 2017-05-11 2019-01-01 美商必治妥美雅史谷比公司 作為irak4抑制劑之噻吩并吡啶及苯并噻吩
TWI776810B (zh) * 2017-05-12 2022-09-11 瑞士商諾華公司 新穎二胺基吡啶衍生物
MY205416A (en) 2017-07-28 2024-10-21 Takeda Pharmaceuticals Co Tyk2 inhibitors and uses thereof
JP7258903B2 (ja) * 2017-11-21 2023-04-17 ブリストル－マイヤーズ スクイブ カンパニー スルホンピリジンアルキルアミド置換ヘテロアリール化合物
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019160875A1 (en) 2018-02-13 2019-08-22 Rutgers, The State University Of New Jersey Antibacterial agents: soluble salts and aqueous formulations of pyronins
CN112118837B (zh) 2018-02-13 2024-07-09 罗格斯新泽西州立大学 抗菌剂：o-烷基氘化派洛宁
WO2019173507A1 (en) 2018-03-06 2019-09-12 Rutgers, The State University Of New Jersey Antibacterial agents : arylalkylcarboxamido phloroglucinols
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
CN111936486B (zh) * 2018-03-22 2023-09-22 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
US12240840B2 (en) * 2018-10-30 2025-03-04 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
CN113271938A (zh) 2018-11-30 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
SG11202105424PA (en) 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2020154474A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020156311A1 (zh) * 2019-01-28 2020-08-06 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
WO2021011724A1 (en) 2019-07-18 2021-01-21 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
KR20220035447A (ko) 2019-07-18 2022-03-22 브리스톨-마이어스 스큅 컴퍼니 IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물
JP7573596B2 (ja) 2019-07-23 2024-10-25 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
EP4027995A4 (en) 2019-09-13 2023-08-23 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR APPLICATIONS
WO2021158495A1 (en) 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
JP7682191B2 (ja) 2020-02-03 2025-05-23 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ４阻害剤として有用な三環ヘテロアリール化合物
CN112203515B (zh) * 2020-03-11 2022-08-02 西北农林科技大学 N-苄基苯甲酰胺类化合物作为除草剂的用途
EP4136073A1 (en) * 2020-04-14 2023-02-22 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
KR20230004771A (ko) 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
JP7537002B2 (ja) * 2020-08-07 2024-08-20 南京薬石科技股▲フン▼有限公司 Ｃｄｋ９阻害剤およびその使用
CN114181257B (zh) * 2020-09-14 2025-02-14 四川科伦博泰生物医药股份有限公司 吡啶类化合物，包含其的药物组合物，其制备方法及其用途
EP4232425A4 (en) 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
AU2021413371A1 (en) 2020-12-30 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AU2022215844A1 (en) 2021-02-02 2023-09-14 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN117098757A (zh) 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
AU2022220043A1 (en) 2021-02-15 2023-08-31 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
AU2022222470A1 (en) * 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
US20240189309A1 (en) * 2021-02-19 2024-06-13 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022223497A1 (en) * 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
EP4319756A4 (en) 2021-04-09 2025-02-26 Nimbus Clio, Inc. CBL-B MODULATORS AND USES THEREOF
CN119013277A (zh) 2021-10-25 2024-11-22 凯麦拉医疗公司 Tyk2降解剂和其用途
CN118302168A (zh) 2021-10-29 2024-07-05 凯麦拉医疗公司 Irak4降解剂和其制备
TW202339749A (zh) * 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Ｔｙｋ２抑制劑及其組合物和方法
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
EP4472967A2 (en) 2022-01-31 2024-12-11 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN116693449A (zh) 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN119585250A (zh) * 2022-04-19 2025-03-07 蓝图药品公司 Kit抑制剂
EP4532485A1 (en) * 2022-05-27 2025-04-09 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
IL318576A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd Pyridoxine-substituted GPR84 antagonists and their uses
KR20250057800A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
WO2024249855A1 (en) * 2023-06-02 2024-12-05 Idrx, Inc. Combination therapy comprising kit inhibitors for use in the treatment of cancer
TW202529769A (zh) 2023-09-21 2025-08-01 日商武田藥品工業股份有限公司 Ｔｙｋ２抑制劑及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044162A1 (en) * 2007-10-05 2009-04-09 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
JPWO2010058846A1 (ja) * 2008-11-21 2012-04-19 アステラス製薬株式会社 ４，６−ジアミノニコチンアミド化合物
JP2014500254A (ja) 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044162A1 (en) * 2007-10-05 2009-04-09 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use

Also Published As

Publication number Publication date
IL238554A0 (en) 2015-06-30
JP2016506368A (ja) 2016-03-03
CN104781252A (zh) 2015-07-15
SG11201503396UA (en) 2015-05-28
MX2015005272A (es) 2015-07-14
CN104781252B (zh) 2017-11-17
WO2014074660A1 (en) 2014-05-15
KR20150081338A (ko) 2015-07-13
BR112015010244A8 (pt) 2019-10-01
EP2922841A1 (en) 2015-09-30
CA2890929A1 (en) 2014-05-15
AU2013341185A1 (en) 2015-07-02
EP2922841B1 (en) 2017-06-07
TW201422587A (zh) 2014-06-16
JP6259463B2 (ja) 2018-01-10
EA201590913A1 (ru) 2015-10-30
BR112015010244A2 (pt) 2017-07-11
EP2922841B8 (en) 2017-08-02
AR093403A1 (es) 2015-06-03
US9315494B2 (en) 2016-04-19
AU2013341185B2 (en) 2017-07-13
TWI620737B (zh) 2018-04-11
EA028526B1 (ru) 2017-11-30
US20150307483A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
KR102233252B1 (ko) ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
KR102195194B1 (ko) ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 아미드-치환된 헤테로시클릭 화합물
KR102186633B1 (ko) Il-12, il-23 및/또는 ifn알파 반응의 조정제로서 유용한 알킬-아미드-치환된 피리딜 화합물
KR102531036B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
JP6458038B2 (ja) ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
JP2019532092A (ja) Ｉｌ−１２、ｉｌ−２３および／またはｉｆｎアルファ応答の調節剤として有用なヘテロ二環化合物
HK40083010A (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HK40010074B (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HK40010074A (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HK1215255B (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150603

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181106

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200319

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200918

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210310

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210323

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210323

End annual number: 3

Start annual number: 1

PG1601 Publication of registration